Preemptive shaming assault on Novartis’ CAR-T pioneer underscores a disconnect on R&D costs
It’s no secret that taxpayers fund a lot of the basic science work done in the US. But should that early research support for new drugs translate into lower prices?
A group called Patients for Affordable Drugs thinks so, launching a preemptive strike against Novartis’ CAR-T drug CTL019— now up for an approval — demanding fair pricing in light of the $200 million-plus that was used to back the translational work on CAR-T in general. There’s no breakdown on what slice of that helped Novartis.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.